Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Sensing ENdometriosiS On Portable Auxiliary Devices

Project description

Revolutionising endometriosis detection through smart femtech biosensors

The EU-funded SENSOPAD project is pioneering a femtech solution set to revolutionise the diagnosis and monitoring of endometriosis (ED), a chronic inflammatory disease affecting over 190 million individuals worldwide. The project integrates two complementary biosensing tools. sensoPAD is a smart layer pad embedded with biochemical and electrochemical sensors that detect ED-related proteins through colour change and RFID signalling; it also incorporates plastic antibodies for autonomous and continuous monitoring. sensoMFgFET is a portable clinical point-of-care device that uses microfluidics and graphene-based bioelectronics to detect ED-specific genetic markers. Both systems are supported by an AI-enabled mobile app and cloud platform for real-time analysis and feedback. The SENSOPAD system enables early, non-invasive and accessible detection, empowering users and transforming the landscape of reproductive healthcare.

Objective

SENSOPAD initiative heralds a transformative era in women's health by addressing the longstanding challenges posed by Endometriosis (ED). ED's early detection is often underdiagnosed due to its asymptomatic nature, pivotal for improved health outcomes and reduced healthcare costs. SENSOPAD introduces two pioneering ED sensing systems: sensoPAD, seamlessly integrated into sanitary pads, and sensoMFgFET, a portable Point-of-Care (POC) device.
SensoPAD comprises three Biological Processing Units (BPU) - BPU-1, BPU-2, and BPU-3 - ensuring continuous monitoring. BPU-1 combines an electrochemical sensor with RFID, while BPU-2 merges a chemical-based fuel cell with an electrochromic cell. BPU-3, an energetically autonomous unit, synergizes BPU-1 and BPU-2 capabilities for seamless monitoring. SensoMFgFET, a POC device, utilizes microfluidic systems and bio-conjugated gFET with RFID functionality, capturing specific DNA SNPs from the menstrual fluid as early ED indicators. Both devices are complemented by a user-friendly mobile application enabling real-time data acquisition and analysis. An advanced cloud platform integrated with AI enhances diagnostic accuracy. This innovative approach shifts the paradigm in ED detection, empowering women, clinicians, and healthcare systems.
SensoPAD detects biomarkers, providing insights during menstrual cycles. If concerns arise during its use, users transition to sensoMFgFET at clinical points, combining at-home convenience with clinical precision. SENSOPAD aims to reduce ED diagnosis time from eight years to days, enabling early treatment, preventing symptom deterioration, optimizing infertility care, and streamlining healthcare journeys. Integrating SENSOPADs with a mobile app and AI-enriched cloud platform ensures accurate, cost-effective diagnostics, detecting silent instances of ED, and signifies a paradigm shift, fostering informed, proactive, and inclusive healthcare decisions for women worldwide.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-CL4-2023-RESILIENCE-01-TWO-STAGE

See all projects funded under this call

Coordinator

ETHNICON METSOVION POLYTECHNION
Net EU contribution
€ 990 000,00
Address
HEROON POLYTECHNIOU 9 ZOGRAPHOU CAMPUS
157 72 ATHINA
Greece
Region
Αττική Aττική Κεντρικός Τομέας Αθηνών
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (11)

Partners (2)